Blockade Medical Receives CE Mark Approval for the Barricade Coil System

July 20, 2012—Blockade Medical (Irvine, CA) announced that it has received CE Mark approval for its Barricade coil system to remove or endovascularly occlude blood flow in vascular abnormalities of the neurovascular and peripheral vessels.

In its press release, the company advised that the Barricade coil system is approved in "10 & 18 framing, filling, and finishing coil configurations" that are designed to provide safe and efficient therapeutic options for treating cerebral aneurysms. Blockade plans to immediately commence European and Latin American commercialization in territories that recognize the CE Mark.

Endovascular neurosurgeon Raymond Turner, MD, of the Medical University of South Carolina in Charleston serves as clinical advisor to the company. “From my initial experience, the Barricade coil system offered competitive performance in terms of deliverability, aneurysm conformability, filling, and finishing,” he commented in the company press release. “The framing coil allows me to frame and fill the aneurysm effectively while delivering coils without sacrificing catheter position. The system also offers long filling and soft finishing coils to enable complete aneurysm embolization.”

According to the announcement, the Barricade system is the first product offering from Blockade Medical. Blockade was formed in the fall of 2011 with a focus on technologies for the endovascular management of hemorrhagic stroke and neurovascular disease. The company is developing a pipeline of products to complement its coil embolization line.